Skip to main content
Smart Investors Daily
SG

NASDAQ · SGMT

Sagimet Biosciences Inc.

Healthcare · Biotechnology

$9.08

Down-$0.54 (-5.61%)

Updated Nov 21, 2026, 2:58 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
196.86M
P/E ratio
-3.57
Dividend yield
0.00%
52-week range
$4.50 – $11.45
Volume
1.5M
Avg. volume
561.82K

Price performance · SGMT

SGMT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

SGMT closed at $9.08 after 21 trading sessions, down 5.22% for the selected period.

Last close
$9.08
Period change
-5.22%
Period low
$9.08
Period high
$11.41
Daily close
View OHLC price history
SGMT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$9.32$9.40$8.832$9.081.5M
Nov 19, 2026$10.11$10.4241$9.575$9.621.03M
Nov 18, 2026$9.86$10.27$9.81$10.11932.92K
Nov 17, 2026$10.09$10.20$9.64$9.85843.62K
Nov 16, 2026$10.10$10.456$9.91$10.131.02M
Nov 13, 2026$10.79$10.84$9.96$10.22759.44K
Nov 12, 2026$11.03$11.31$10.81$10.931.44M
Nov 11, 2026$10.93$11.44$10.80$11.411.79M
Nov 10, 2026$10.66$11.005$10.48$10.891.57M
Nov 9, 2026$9.945$10.86$9.70$10.831.09M
Nov 6, 2026$9.25$9.87$9.0201$9.85857.93K
Nov 5, 2026$9.83$9.95$9.055$9.121.15M
Nov 4, 2026$10.25$10.43$9.64$9.99756.45K
Nov 3, 2026$9.80$10.16$9.6593$9.95636.84K
Nov 2, 2026$9.92$9.97$9.615$9.69736.09K
Oct 30, 2026$10.41$10.535$9.82$9.92989.15K
Oct 29, 2026$10.82$10.92$10.27$10.43746.45K
Oct 28, 2026$10.32$10.76$10.2586$10.741.24M
Oct 27, 2026$9.58$10.48$9.55$10.421.11M
Oct 26, 2026$9.61$9.70$9.41$9.56767.19K
Oct 23, 2026$9.95$9.95$9.495$9.58694.95K

Latest SGMT news

The latest Smart Investors Daily articles mentioning SGMT.

SGMT research

Overview

Company profile and research snapshot.

Company profile

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$6.00
Implied upside
—
Analysts
16
SGMT recent ratings
DateFirmRatingTarget
Nov 13, 2026Canaccord GenuityBuy—
Oct 5, 2026HC Wainwright & Co.Buy—
Oct 2, 2026GuggenheimBuy—
Oct 1, 2026OppenheimerOutperform—
Oct 1, 2026CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026Completed underwritten offering of Series A Common S

Yahoo · Oct 29, 2026

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, in Boston, MA with a fireside chat at 10:30am ET (link here). Inducement Grant In connection with the hiring of two employees

Yahoo · Oct 23, 2026

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that its strategic partner, Sagimet Biosciences Inc. ("Sagimet"), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, had dosed the first patient in AURORA, Sagimet's pivotal U.S. Phase III clinical trial of denifanstat (ASC40) in adults and adolescents aged 12 years and older with moderate to severe acne. AURORA is intended to support a potential U.S. Ne

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.